GENHOUSE BIO HKEX IPO Application Lapsed; Multiple Globally Competitive Drug Candidates Fail to Secure HKEX Listing

NewTimeSpace · 2026/07/16 10:21 · By Zehong Cheng

NewTimeSpace News: The Hong Kong listing application of Suzhou Genhouse Bio Co., Ltd., filed on 16 January 2026, has lapsed upon expiry of the six-month validity period. Huatai International acted as the original sole sponsor. Established in 2014, the biotech firm focuses on potential best-in-class targeted therapies for oncology. Its core asset GH21, a potential best-in-class allosteric SHP2 inhibitor, is currently in Phase II clinical trials.

NewTimeSpace News: The listing application submitted by Suzhou Genhouse Bio Co., Ltd. to HKEX on 16 January 2026 has lapsed following the expiration of the six-month timeline. Huatai International served as the original sole sponsor.

The Company is a biopharmaceutical company with a differentiated and robust self-developed pipeline of innovative drug candidates built around the RAS signalling pathway and synthetic lethality mechanisms. According to CIC, several of its drug candidates hold globally leading positions in terms of clinical advancement against respective targets.

GH21, the flagship product, is a potential best-in-class allosteric SHP2 inhibitor undergoing Phase II clinical trials. The Company secured IND approval for GH21 monotherapy in advanced solid tumours in November 2021, initiated Phase I trials in May 2022 and completed Phase I studies in March 2025. For combination regimens, IND approvals have been obtained for GH21 combined with sotorasib and osimertinib, with relevant clinical trials advancing in China. The Group’s R&D capabilities have been recognised via multiple prestigious accolades including the 2025 National Science and Technology Major Project and 2025 Jiangsu Provincial Science and Technology Major Project.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Genhouse Bio IPO IPO application lapsed